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ABSTRACT
CONTEXT AND OBJECTIVE: Bariatric surgery has been an effective alternative treatment for morbid obesity 
and has resulted in decreased mortality, better control over comorbidities and reduced use of drugs. The 
objective of this study was to analyze the impact of bariatric surgery on medication drug and nutritional 
supplement use. 
DESIGN AND SETTING: Longitudinal study of before-and-after type, on 69 morbidly obese patients in a 
public hospital in Porto Alegre. 
METHODS: Through interviews, the presence of comorbidities and use of drugs with and without pre-
scription were evaluated. 
RESULTS: Among the 69 patients interviewed, 85.5% had comorbidities in the preoperative period, with 
an average of 2.3 (± 1.5) per patient. The main comorbidities reported were hypertension, diabetes and 
dyslipidemia. 84.1% of the patients were using prescribed drugs in the preoperative period. The mean 
drug use per patient was 4.8, which decreased to 4.4 after the procedure. The surgery enabled significant 
reduction in use of most antidiabetic (84%), antilipemic (77%) and antihypertensive drugs (49.5%). On 
the other hand, there was a significant increase in use of multivitamins and drugs for disorders of the 
gastrointestinal tract. The dosages of most of the drugs that continued to be prescribed after surgery were 
decreased, but not significantly.
CONCLUSION: After bariatric surgery, there were increases in the use of vitamins, gastric antisecretory 
drugs and antianemic drugs. Nevertheless, there was an overall reduction in drug use during this period, 
caused by suspension of drugs or dose reduction. 
RESUMO
CONTEXTO E OBJETIVO: A cirurgia bariátrica tem sido uma alternativa efetiva de tratamento para a obe-
sidade mórbida, resultando na diminuição da mortalidade, melhor controle das comorbidades e redução 
no uso de medicamentos. O objetivo deste estudo foi analisar o impacto da cirurgia bariátrica sobre a 
utilização de  medicamentos e suplementos nutricionais. 
TIPO DE ESTUDO E LOCAL: Estudo longitudinal do tipo antes e depois com 69 pacientes obesos mórbi-
dos em um hospital público de Porto Alegre. 
MÉTODOS: Nas entrevistas, foram avaliados a presença de comorbidades e o uso de medicamentos com 
e sem prescrição médica. 
RESULTADOS: De 69 pacientes entrevistados, 85,5% apresentaram comorbidades no período pré-cirúrgi-
co, média de 2,3 (± 1,5) por paciente. As principais comorbidades relatadas foram hipertensão, diabetes e 
dislipidemias. 84,1% dos pacientes estavam em uso de medicamentos sob prescrição médica, no período 
pré-cirúrgico. A média de uso de medicamentos por paciente foi de 4,8, reduzindo para 4,4 após o pro-
cedimento. A cirurgia proporcionou diminuição significativa do uso da maioria dos antidiabéticos (84%), 
antilipêmicos (77%) e anti-hipertensivos (49,5%). Por outro lado, observou-se aumento significativo na 
utilização de multivitamínicos e medicamentos para desordens do trato gastrointestinal. A maior parte 
dos medicamentos que continuaram sendo prescritos após a cirurgia teve sua dose reduzida, no entanto, 
esta redução não foi significativa. 
CONCLUSÃO: Após a cirurgia bariátrica, observou-se aumento na utilização de vitaminas, antisecretores 
gástricos e antianêmicos. No entanto, de forma geral, houve redução na utilização de medicamentos nes-
te período, ocasionada pela suspensão de medicamentos ou redução de doses.
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INTRODUCTION
Chronic non-communicable diseases are one of the biggest pub-
lic health issues today.1 Obesity stands out in this regard and has 
been officially acknowledged by the World Health Organization 
(WHO) as a chronic disease.2
The number of obese individuals has been increasing world-
wide and has reached an average of 30% of the adult popula-
tion in some countries.3 In Brazil, poor dietary habits have been 
reflected in the population’s health and in increasing prevalence 
of overweight. More than half of all Brazilians (51%) are now 
overweight, and 17% of these individuals are obese.1
Fighting this rapid growth is one of the biggest challenges 
for world health, given that obesity is frequently associated with 
a vast array of comorbidities, such as systemic arterial hyperten-
sion, type 2 diabetes mellitus, dyslipidemia, obstructive sleep 
apnea, cardiovascular diseases and some types of cancer.4-8 
Most  patients with high blood pressure are overweight,9 and 
hypertension is six times more frequent among obese individuals 
than among those with normal weight.10
The alternatives to clinic treatment for reducing weight 
among patients with morbid obesity are limited, and the long-
term outcomes are relatively inefficient.11 Bariatric surgery 
seems to be a viable option for treating morbid obesity, since it 
has been shown to be effective in maintaining the weight loss. 
A significant improvement in comorbidities and even their 
regression may be observed in most patients who undergo this 
surgical procedure for weight loss.10 This surgical procedure has 
been shown to enable control over glucose levels, even leading 
to remission of diabetes.12 The quick and sustained improve-
ment in glucose homeostasis that this procedure provides has 
made it the gold-standard metabolic procedure and treatment 
for diabetic patients with morbid obesity.13 Comorbidity reduc-
tions are reflected in diminished drug use during the postoper-
ative period, and discontinuation of drug therapy for some dis-
eases, thus resulting in reduced expenditure on drugs and other 
healthcare services.10,14-18
In addition, bariatric surgery extends survival, decreases 
occurrences of cardiovascular events and is also associated with 
greater reduction of mortality due to cardiovascular diseases, 
myocardial infarction, stroke, diabetes and cancer, in compari-
son with obese individuals who do not undergo this surgery.10,19,20 
The reduction in the risk of myocardial infarction, stroke and 
adverse cardiovascular events is approximately 50% after this 
surgery, in comparison with individuals who did not undergo 
the procedure.19
If, on the one hand, bariatric surgery reduces the need for 
medication to treat comorbidities; on the other hand, the restric-
tive and disabsorptive procedures involved pose a higher risk 
of deficiencies of vitamins and minerals.21 However, studies 
assessing drug use and their respective dosages after bariatric 
surgery are still scarce. 
OBJECTIVE
Within this context, this study aimed to assess the impact of bar-
iatric surgery on medication drug use among morbidly obese 
patients, before and after the procedure, focusing mainly on the 
number of drugs used, drug classes and posology. 
METHODS
This was a longitudinal study of before-and-after type, car-
ried out between 2008 and 2011 in the endocrinology clinic of 
the service for assisting morbidly obese individuals at Hospital 
Nossa Senhora da Conceição (HNSC) in the city of Porto Alegre, 
which works under the National Health System (Sistema Único 
de Saúde, SUS). Through this service, four to five operations per 
month are performed on patients coming from several regions of 
the state of Rio Grande do Sul. The clinic offers care provided by 
physicians (endocrinologist, surgeon and psychiatrist), psychol-
ogists, nutritionists and nurses. 
The patients eligible for surgical treatment are those with 
BMI greater than 40 kg/m² or greater than 35 kg/m² in associa-
tion with comorbidities, after failure in applying traditional mea-
sures for weight loss. They need to be psychologically capable of 
following dietary orientation during the postoperative period, as 
well as presenting absence of endocrine causes of obesity.22-24
The sample size was estimated to be 52 patients, tak-
ing into consideration the reduction in drug use for treating 
hypertension and cardiovascular disease (HT/CVD) that has 
been reported in the literature.25 The reduction in drug use 
expected after the intervention was 49%. Considering the prob-
ability that some patients would be lost from the follow-up, it 
was decided to increase the sample size by 30%. Thus, after the 
research project had been approved by the HNSC Research 
Ethics Committee (report no. 146/08), and after potential par-
ticipants had signed an informed consent statement authoriz-
ing data use, 69 individuals with morbid obesity (convenience 
sampling), who were waiting for biliopancreatic diversion with 
duodenal switching (BPD-DS) and Roux-en-Y gastric bypass 
(RYGBP), were interviewed. 
Individuals aged over 18 years with class III obesity (body 
mass index, BMI, greater than 40 kg/m2) and those with BMI 
greater than 35 kg/m2 in association with comorbidities, who 
were willing to participate in the study, had presented stable obe-
sity for at least five years and had had at least two years of pre-
vious inefficient clinical treatment, were included in this study. 
Patients who did not adhere to preoperative monitoring appoint-
ments, had comprehension difficulties (which made them unable 
to make decisions) or had already undergone another surgical 
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procedure with the aim of losing weight (gastric sleeve) were 
excluded from the study. 
Data were gathered through 40-minute interviews that were 
conducted with all patients one day before the procedure and 
again six months after it. A structured questionnaire was used to 
assess the variables of gender, age, weight, drug use, reasons for 
undergoing the surgery and comorbidities. To confirm the pres-
ence of comorbidities, drug use, weight and height, some data 
from the patients’ records were used.
Information on drug use at the time of the interviews was 
initially gathered through the open question “What medica-
tions do you take?” For each drug, the name, daily dose, indi-
cation and whether its use was through self-medication or 
prescription were registered. To minimize data loss through 
forgetfulness, the participants were also asked about their drug 
use by specifying organs or systems (for example: “Do you take 
any drug for heart disease?”).
The proportion of patients using each drug was calculated 
taking into consideration the total number of patients using the 
drug at each time: preoperatively, n = 69; postoperatively, n = 64. 
To evaluate dose variability, the sum of the doses of each drug 
divided by the number of patients using this drug at each time 
was calculated.
The data were double-input into the Epi Data 2.1a. soft-
ware. They were analyzed through the Statistical Package for 
the Social Sciences (SPSS) version 18.0 and the Winpepi soft-
ware. Comparative and descriptive analyses were performed, 
expressing frequency, average, standard deviation and P-values. 
McNemar’s chi-square test was applied to compare the numbers 
of patients using drugs before and after the procedure. Student’s t 
test was applied to analyze the dosages. P values ≤ 0.05 were con-
sidered significant. 
RESULTS
During the preoperative period, 69 patients who were sched-
uled to undergo bariatric surgery were monitored. There were no 
refusals to participate. However, after the procedure, there was a 
loss of five cases: four patients did not return to the consultations 
in the hospital and one patient died. The majority of the patients 
participating in this study were women (91.3%) and married 
(46.5%). Their mean age was 42.3 (± 10.4); they had a mean of 9 
(± 2.3) years of education and had undergone a mean of 4 (± 1.3) 
years of preoperative monitoring. Their mean BMI before the 
operation was 51.07 (± 7.8) kg/m², and after the operation it was 
35.9 (± 7.2) kg/m2 (Table 1). 
During the preoperative period, 85.5% of the patients pre-
sented one to five comorbidities associated with obesity, with 
a mean of 2.33 (± 1.47) per patient. The patients between 20 
and 25 years of age did not present any comorbidities. On the 
other hand, comorbidities were present in all patients aged over 
49  years. Hypertension, diabetes, high cholesterol level, hypo-
thyroidism, arthrosis/arthritis, asthma, depression and circula-
tory problems were the main issues reported prior to surgery. 
After the procedure, significant reductions in hypertension and 
diabetes were observed. Dyslipidemia, hypothyroidism, arthro-
sis/arthritis and depression presented reductions, but not signifi-
cantly (Table 2). 
The surgical technique most often used was gastric bypass 
(91.4%). The subjects mentioned the following as the main rea-
sons for undergoing the surgery: desire to have better health 
(42.9%), desire for better quality of life (11.1%), desire for 
weight loss (11.1%), tiredness (6.3%), difficulty in moving 
around (6.3%), sore legs (4.8%), backache (3.2%) and preju-
dice (3.2%). 
Among the 69 patients interviewed before the surgery, 84.1% 
reported using drugs through medical prescription, whereas 
73.9% did this through self-medication. At the time of the post-
operative assessment, 82.6% and 50.7% took drugs, respectively 
with and without prescription. Use of 328 drugs was observed 
before the operation, with an average of 4.8 drugs per patient, 
SD = standard deviation; BMI = body mass index.
Table 1. Characteristics of patients undergoing bariatric surgery at 
Hospital Nossa Senhora da Conceição between 2008 and 2011 (n = 69)
Baseline characteristics Mean (SD), % (n)
Mean age (years) 42.3 (10.4)
School education (years) 9 (2.3)
Preoperative monitoring (years) 4 (1.3)
Marital status
Married 62.3% (43)
Single 37.7% (26)
Gender
Female 91.3% (63)
Male 8.7% (6)
BMI
Preoperative 51.1 (7.8) kg/m2
Postoperative 35.9 (7.2) kg/m2
*P ≤ 0.05 (chi-square test).
Table 2. Main comorbidities shown at pre and postoperative 
assessments
Comorbidities
Preoperative number 
of patients with 
comorbidities
n = 69
Postoperative number 
of patients with 
comorbidities
n = 64
Hypertension 45 (65.2%) 19 (29.7%)*
Diabetes 20 (28.9%) 4 (6.3%)*
Dyslipidemias 11 (15.9%) 4 (6.3%)
Hypothyroidism 9 (13%) 6 (9.4%)
Arthrosis/arthritis 9 (13%) 4 (6.3%)
Depression 8 (11.6%) 6 (9.4%)
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whereas after the operation this use reduced to 284 drugs, with 
an average of 4.4 per patient. 
A significant reduction in the use of antihypertensive drugs 
(49.5%) was observed, except for propranolol. Decreases in 
the use of antidiabetic (84%), antidepressant (30%), antilipe-
mic (50%), muscle relaxant (33.3%), painkiller (35.3%) and 
anti-inflammatory (78.5%) drugs were also observed, and these 
decreases were significant for the following drugs: metformin, 
fluoxetine, simvastatin, acetylsalicylic acid (ASA), diclofenac and 
paracetamol. On the other hand, there were significant increases 
in the use of vitamin supplements and drugs relating to disorders 
of gastrointestinal tract, such as omeprazole (Table 3).
Moreover, reductions in daily dosages were observed for 
antidiabetic, antilipemic, antidepressant, antithrombotic and 
most antihypertensive drugs. The differences observed in rela-
tion to the dosages were not significant.
DISCUSSION
Our results showed that use of antidiabetic, antihypertensive, 
painkiller, antilipemic and antidepressant drugs had decreased 
by the time of the assessment six months after surgery. However, 
increases in the numbers of drugs used to treat gastrointestinal 
disorders, anemia and vitamin deficiency were observed.
Among the patients who kept on using drugs after the sur-
gery, reductions in dosages were observed in most of the cases, 
mainly in relation to antihypertensive drugs (except for hydro-
chlorothiazide), antidiabetic drugs and antidepressants; however, 
these reductions were not significant.
SD = standard deviation; *McNemar’s chi-square test; †oxymetazoline (1 patient), xylometazoline (1), salbutamol (2), fenoterol (1), salmeterol and fluticasone (1), 
formoterol and budesonide (2), beclometasone (1), dexchlorpheniramine (1) and loratadine (1).
Table 3. Differences observed in relation to the main therapeutic classes, drugs and mean daily dosages used before and after bariatric surgery
Therapeutic class/
system
Drug
Patients using drugs
n (%)
P*
Mean prescribed daily dosage, mg (SD)
Dosage 
difference %Pre
(n = 69)
Post
(n = 64)
Pre Post
Antihypertensive
Hydrochlorothiazide 30 (43.5) 17 (24.6) 0.001 26.27 (± 6.94) 29.38 (± 18.87) +11.8
Captopril 26 (37.7) 15 (21.7) 0.003 85.96 (± 41.04) 67.67 (± 47.09) -21.28
Propranolol 10 (14.5) 6 (8.7) 0.125 104 (± 50.60) 80 (± 25.30) -23.08
Enalapril 9 (13.0) 2 (2.9) 0.016 26.11 (± 17.10) 25 (± 21.21) -4.25
Others 22 (31.9) 9 (13.0) - None None None
Antidiabetic
Metformin 18 (26.1) 3 (4.3) 0.000 1802.78 (± 784.5) 850 -52.85
Insulin 3 (4.3) 1 (1.4) 0.500 45.67 (± 47.18) 30 -34.31
Others 4 (5.8) 0 - None None None
Antidepressive
Fluoxetine 27 (39.1) 16 (23.2) 0.013 63.65 (± 32.11) 48 (± 25.97) -24.6
Citalopram 8 (11.6) 4 (5.8) 0.125 40 (± 17.73) 36.67 (± 5.77) -8.3
Others 5 (7.2) 8 (11.6) - None None None
Antilipemic Simvastatin 13 (18.8) 3 (4.3) 0.006 23.85 (± 9.61) 23.33 (± 15.27) -2.18
Antithrombotic
Acetylsalicylic acid 7 (10.1) 1 (1.4) 0.031 133.33 (± 51.64) 100 -24.9
Others 1 (1.4) 2 (2.9) - None None None
Anti-inflammatory
Diclofenac 7 (10.1) 1 (1.4) 0.031 116.67 (± 57.73) None None
Ibuprofen 6 (8.7) 1 (1.4) 0.125 300 (± 300) None None
Others 1 (1.4) 1 (1.4) - None None None
Painkillers
Paracetamol 39 (56.5) 19 (29.7) 0.001 821.48 (± 592.29) 1000 (± 707.11) +21.73
Metamizole 5 (7.2) 11 (15.9) 0.109 500 500 None
Others 7 (10.1) 2 (2.9) - None None None
Muscle relaxants
Carisoprodol 6 (8.7) 6 (8.7) 1.000 None None None
Orphenadrine 6 (8.7) 2 (2.9) 0.289 None None None
Respiratory system† 11 (15.9) 5 (7.25) - None None None
Vitamins and mineral 
supplements
Multivitamins 1 (1.4) 39 (56.5) 0.000 None None None
Antianemic
Folic acid 1 4 (5.8) 0.250 None None None
Cyanocobalamin - 3 (4.3) - None None None
Others - 3 (4.3) - None None None
Gastric antisecretory 
agents
Omeprazole 9 (13.0) 31 (44.9) 0.000 24.44 (± 8.82) 22.92 (± 8.06) -6.22
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Antidiabetic drugs
The number of patients using antidiabetic drugs decreased by 
84% during the postoperative period. Reductions in mean daily 
dosages of antidiabetic drugs were also observed. Our results 
are consistent with those of other authors. Maciejewski et al.26 
reported that there was a 50% reduction in the use of antidia-
betic drugs within one year after bariatric surgery. Additionally, 
Potteiger et al.27 and Narbro et al.28 reported that there were sig-
nificant reductions in the numbers and cost of drugs used to 
treat diabetes relating to obesity, after surgery. Importantly, the 
features of the population and the follow-up period need to 
be taken into account in assessing these proportions, because 
the  impact of surgery on antidiabetic drug use may vary 
according to these factors.29
The great majority of the patients with type 2 diabetes expe-
rience more favorable results from clinical examinations, after 
undergoing bariatric surgery. The mortality rate associated with 
diabetes has also been significantly reduced.10 A more recent study 
that assessed the long-term effects of bariatric surgery on dia-
betic patients observed that glucose control and remission from 
diabetes were possible in 89.2% and 64.7% of the patients, respec-
tively.30 Similar findings had already been reported previously.31
Furthermore, reduction of diabetes has been found to occur 
more frequently among patients who underwent gastric bypass 
surgery that excluded the duodenum from the nutrient pathway 
and changed the bowel metabolism, thus reducing insulin resis-
tance faster.32 Therefore, the significant decrease in antidiabetic 
drug use observed in our study might be related to the surgical 
technique used on most subjects (91%). 
Recent studies have also suggested that the remission mecha-
nism of this comorbidity in the postoperative period may be cat-
egorized into two groups: unconnected with weight loss and con-
nected with it. Although weight loss is an aspect common to all 
techniques, gastric bypass has shown improvement in diabetes 
over the short term, regardless of weight loss.33,34 The underlying 
mechanisms for this are still being studied.35-42
Metformin, the most widely used antidiabetic drug, is 
absorbed slowly and incompletely by the gastrointestinal tract, 
mainly from the small intestine onwards. Studies suggest that 
this drug reaches saturation of absorption, since its concentra-
tion in the plasma does not increase with administration of ever-
higher dosages.43
Metformin dosage has to be carefully individualized, based 
on patients’ tolerance and response. Side effects, especially gas-
trointestinal effects, are observed in approximately 5 to 50% of 
the patients and seem to be related to dosage.43
Regarding pharmacokinetics, few studies have focused on 
antidiabetic drug absorption after bariatric surgery. However, 
Aron-Wisnevsky44 observed that metformin bioavailability 
seems to increase after gastric bypass, thus increasing the risk of 
toxicity. Therefore, the decrease in dosage observed in our study 
might be partly related to these findings.
Antihypertensive drugs
A reduction in the number of patients using antihypertensive 
drugs during the postoperative period was observed (49.5%) 
The mean daily dosages became smaller for most drugs, except 
for hydrochlorothiazide. Increases in dosage may be due to exclu-
sion of other antihypertensive drugs. According to the BAROS 
system (Bariatric Analysis and Reporting Outcome System), 
arterial hypertension is resolved after bariatric surgery when 
patients continue to use diuretics alone.45,46
Regarding the reduction in the number of patients who were 
using antihypertensive drugs, our findings were similar to those 
reported by other authors.26-28,47,48 Partial or complete improve-
ment was shown within 12 months after undergoing bariat-
ric surgery, especially among the patients who had undergone 
gastric bypass,10,47 thus reducing the need for antihypertensive 
drugs.49,50 It seems again that our results were somehow related 
to the technique used for the majority of our patients, i.e. gas-
tric bypass.
Reductions in plasma catecholamines and renin activity 
brought about by weight loss is associated with decreased sympa-
thetic activity, and is likely to be a determining factor for control-
ling hypertension.51-53 Thus, it can be suggested that these factors 
may have contributed towards decreased antihypertensive drug 
use after loss of excessive weight due to the bariatric surgery. 
Antilipemic drugs
Approximately 50% of the patients undergoing surgery for weight 
loss present dyslipidemia, which is a major factor relating to mor-
bidity and mortality rates.16,54 Weight loss significantly improves 
patients’ lipid profiles. Reductions in triglycerides, total choles-
terol and low-density lipoprotein (LDL) levels, and increases in 
high-density lipoprotein (HDL) occur. Within less than one year, 
most patients who previously needed lipid-lowering drugs are 
able to discontinue their use.16
Our results confirm the findings from previous studies.16,54 
A marked decrease in the number of patients using simvastatin 
was observed. These results suggest that not only was the surgery 
effective for weight loss, but also it was an efficient alternative 
for treating dyslipidemia among these severely obese individu-
als. Improvement in lipid profile is related to the technique used, 
and disabsorptive techniques cause more significant changes. 
However, the mechanisms involved in dyslipidemia reduction 
following bariatric surgery have not been clarified yet.10
Regarding the dosage of antilipemic drugs, there are some 
reports on atorvastatin in the literature, suggesting that its 
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bioavailability increases after the surgical procedure, thus allow-
ing reduction of the dosage.44 Nevertheless, it is not known 
whether the same occurs with simvastatin. In our study, for 
patients who continued using simvastatin after surgery, there was 
no clinically significant reduction in daily dosage use.
Multivitamins and antianemic drugs
Multivitamin supplementation is recommended during the 
postoperative period, in order to correct nutritional deficien-
cies,55,56 especially those relating to vitamins B12, A and D, thia-
mine, folate and minerals such as iron, zinc and calcium.57,58 Such 
deficiencies frequent occur after bariatric surgery and relate to 
decreased food intake and physiological changes produced by the 
surgery.59,60
Gastric bypass changes how food passes along the gastroin-
testinal tract and leads to poor nutrient absorption, given that 
food is exposed to the jejunum earlier than usual, through exclu-
sion of part of the gastric and duodenal surface.61 The absorbent 
surface area and solubility, and consequently drug bioavailability, 
are affected by this technique.44,57
Our results support previous findings in that they indicated 
that there was a significant increase in vitamin use that might be 
related to the surgical technique (91%), as well as decreased food 
intake after the surgery. Furthermore, an increase in the use of 
antianemic drugs during the postoperative period was observed. 
Iron deficiency during this period was very evident.21
Gastric antisecretory agents
Unlike our study, in which a significant increase in the use of 
antisecretory agents was observed, Crémieux55 and Fontana and 
Wohlgemuth62 reported reductions in the use of these drugs for 
up to three years after the surgery. This decrease might be con-
nected with the reduced occurrence of gastroesophageal reflux 
over time, which might remain stabilized for up to three years. 
The difference in the results reported by these authors,55 in com-
parison with our study, might be associated with the duration 
of the postoperative follow-up among the patients and with the 
standard of service rendered. 
Development of stomach ulcers is one of the biggest 
and most common complications associated with the gas-
tric bypass technique,63,64 and it is reported in 1% to 20% of 
the patients after surgery.65,66 Stomach ulcers may develop 
over the short term, possibly associated with technical prob-
lems at the intervention site.67 They are usually located in the 
damaged intestinal mucosa, unable to withstand acidity; they 
may also be located near the anastomosis.66 Stapling during 
the surgery, use of anti-inflammatory drugs or presence of 
Helicobacter pylori (H. pylori) during the preoperative period 
may provoke development of late ulcers. Previous reports 
in the literature suggest that H. pylori damages the muco-
sal barrier, and that this damage persists into the postoper-
ative period. This induces exacerbation of the ulcer, even if 
the organism has already been treated.63,68,69 All these factors 
may have influenced the increased prescription of antisecre-
tory drugs observed in this study.
Antidepressants
There are few studies relating to the effect of bariatric surgery 
on the use of drugs that act on the central nervous system. One 
of the reasons for this is the screening that is done on patients 
before they undergo bariatric surgery, given that the presence of 
moderate or severe psychosis or dementia is one of the exclu-
sion criteria.55 Unlike most other studies, ours showed that the 
use of antidepressants decreased among the patients after the sur-
gical procedure. Use of some classes of antidepressants, especially 
selective serotonin reuptake inhibitors, has been indicated as an 
adjunct in treatments for obesity.43 This factor may be related to 
the decrease observed in our study.
Lopes70 and Segal et al.71 also observed a tendency towards 
improvement in their patients’ psychological functioning. 
Nevertheless, it is known that some psychiatric disorders may 
emerge during this period. 
Over the long term, some authors have observed that several psy-
chiatric conditions have been causes of death during the postopera-
tive period, usually through suicide. Depression has been reported 
to be one of the most frequent late complications (23.4%).72-75
van Hout et al.76 pointed out that the psychiatric effects of 
bariatric surgery might take from 6 to 24 months to emerge. 
It  has been suggested that the levels of anxiety and depression 
probably will not be significantly different six months after sur-
gery,77 and that improvements in depressive conditions might 
only be observed 12 months after the surgery.78
Regarding the daily dosage, decreases were observed in rela-
tion to both fluoxetine and citalopram. According to previous 
reports in the literature, these effects may occur through dis-
continuation of use of selective serotonin reuptake inhibitors 
(SSRIs). Therefore, abrupt discontinuation of these drugs should 
be avoided whenever possible.43 The small reductions in antide-
pressant use and daily dosages observed in our study may have 
been partially related to this, since complete withdrawal of these 
drugs may have serious effects.
Anti-inflammatory drugs and painkillers
The high frequency of use of anti-inflammatory drugs during 
the preoperative period may be explained by the fact that obesity 
contributes towards development of inflammatory diseases in the 
joints. Moreover, anti-inflammatory drugs are efficient possibly 
because obesity is a proinflammatory condition.79
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Inflammatory diseases of the joints are more common in 
obese people probably precisely due to their overweight con-
dition. Therefore, the need for these drugs decreases through 
surgery,80 given that patients have less need for them, for treat-
ing pain, fever and inflammation, after they have lost some 
excess weight.
The use of anti-inflammatory drugs decreased by 78.5%, 
which corroborated previous findings. Furthermore, there was 
also a 35.3% reduction in the use of painkillers, and 33.3% 
regarding muscle relaxants. Among the painkillers, only for 
dipyrone was there an increase in consumption, which may have 
been due to the standard prescription issued by the surgical team 
during the postoperative period. It is possible that this medical 
prescription may have influenced the choice of analgesic in self-
medication situations. It is important to point out that these last 
two drug classes were the ones most often used in self-medica-
tion, thus suggesting that bariatric surgery decreased the need for 
their use among the patients. 
Our results support and reinforce previous findings in the lit-
erature regarding the impact of bariatric surgery on the use of 
some drug classes.28,31
One limitation of our study was the small sample size. 
However, few studies have assessed dosage reductions among 
the drugs that continue to be used after bariatric surgery.81,82 
Consequently, the data presented in this study provide further 
details of the benefits of this procedure for patients.
Within this context, there is a need for more comprehen-
sive studies with larger sample sizes and longer follow-up, espe-
cially in Brazil, where studies correlating weight loss with drug 
use, with pharmacokinetic assessments before and after bariatric 
surgery, are still scarce. Moreover, these studies need to address 
other factors that may have influenced the increase or decrease 
in use of some drug classes, such as adherence to treatment, side 
effects, access to drugs and economic factors, among others. 
With the rampant growth of obesity, implementation of 
prevention policies is also a relevant approach to be considered 
within public health management, so as not only to prevent 
obesity but also to prevent its complications due to associated 
comorbidities, drug use, side effects, reduced quality of life and 
even societal prejudice. 
CONCLUSION
Based on the data obtained, bariatric surgery was observed to 
enable decreased need for some of the drug classes used, and also 
adjustment of the dosages of the drugs that continued to be pre-
scribed. On the other hand, new drug classes were included in 
the patients’ therapeutic plans, such as vitamins, drugs for gastro-
intestinal tract disorders and antianemic drugs, as a result of the 
limitations imposed by the procedure. 
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